对牛津大学的 R21/Matrix-M™ 疟疾疫苗的展望及对全球消除疟疾努力的未来的看法。
A perspective on Oxford's R21/Matrix-M™ malaria vaccine and the future of global eradication efforts.
机构信息
Department of Medicine and Surgery, Ladoke Akintola University Teaching Hospital, PMB 5000, Ogbomoso, Nigeria.
Department of Medicine and Surgery, University of Ilorin, Ilorin, Nigeria.
出版信息
Malar J. 2024 Jan 12;23(1):16. doi: 10.1186/s12936-024-04846-w.
Malaria affects millions of lives annually, particularly in tropical and subtropical regions. Despite being largely preventable, 2021 witnessed 247 million infections and over 600,000 deaths across 85 countries. In the ongoing battle against malaria, a promising development has emerged with the endorsement by the World Health Organization (WHO) of the R21/Matrix-M Malaria Vaccine. Developed through a collaboration between the University of Oxford and Novavax, this vaccine has demonstrated remarkable efficacy, reaching 77% effectiveness in Phase 2 clinical trials. It is designed to be low-dose, cost-effective, and accessible, with approval for use in children under three years old. This perspective paper critically examines the R21/Matrix-M malaria vaccine, its development, potential impact on global malaria eradication efforts, and the challenges and opportunities it presents.
疟疾每年影响数百万人的生命，特别是在热带和亚热带地区。尽管疟疾在很大程度上是可以预防的，但在 2021 年，85 个国家报告了 2.47 亿例感染和超过 60 万例死亡。在与疟疾的持续斗争中，世界卫生组织（WHO）批准 R21/Matrix-M 疟疾疫苗的出现带来了一个有希望的进展。该疫苗由牛津大学和诺华公司合作开发，在 2 期临床试验中显示出了显著的疗效，达到了 77%的有效性。该疫苗设计为低剂量、具有成本效益且易于获得，并已批准用于三岁以下儿童。本文从批判性视角审视了 R21/Matrix-M 疟疾疫苗，包括其研发过程、对全球疟疾消除努力的潜在影响，以及它所带来的挑战和机遇。
Zotero 插件